Could erythropoietin reduce the ovarian damage of cisplatin in female rats?

Gynecological Endocrinology

Volumn 34, Issue 4, 2018, Pages 309-313

  Dayangan Sayan, Cemile ^a   Tulmac, Ozlem Banu ^a   Karaca, Gökhan ^a   Ozkan, Zehra Sema ^a   Yalcin, Selim ^a   Devrim, Tuba ^a   Dindar Badem, Nermin ^a  

^a KIRIKKALE UNIVERSITY   (Turkey)

Author keywords

AMH; Cisplatin; erythropoietin; ovary

Indexed keywords

CISPLATIN; ERYTHROPOIETIN; MUELLERIAN INHIBITING FACTOR; RECOMBINANT ERYTHROPOIETIN; SODIUM CHLORIDE; ANTINEOPLASTIC AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTRAL FOLLICLE; ARTICLE; BLEEDING; CELL DEGENERATION; CELL SIZE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; INFLAMMATION; NONHUMAN; OVARY FOLLICLE CELL; OVARY INSUFFICIENCY; OVARY TISSUE; PRIMORDIAL FOLLICLE; PRIORITY JOURNAL; RAT; ANIMAL; BLOOD; DRUG EFFECT; FEMALE; OVARY; WISTAR RAT;

ANIMALS; ANTI-MULLERIAN HORMONE; ANTINEOPLASTIC AGENTS; CISPLATIN; ERYTHROPOIETIN; FEMALE; OVARY; RATS; RATS, WISTAR;

EID: 85032666685     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.1080/09513590.2017.1395836     Document Type: Article

References (32)

1. Meirow D., Reproduction post-chemotherapy in young cancer patients. Mol Cell Endocrinol 2000;169:123–31.
2. Oktem O, Oktay K., Quantitative assessment of the impact of chemotherapy on ovarian follicle reserve and stromal function. Cancer 2007;110:2222–9.
3. Wallace WH, Shalet SM, Crowne EC, et al. Gonadal dysfunction due to cis-platinum. Med Pediatr Oncol 1989;17:409–13.
4. Mori S, Sawada T, Okada T, et al. Erythropoietin and its derivative protect the intestine from severe ischemia/reperfusion injury in the rat. Surgery 2008;143:556–65.
5. Spandou E, Tsouchnikas I, Karkavelas G, et al. Erythropoietin attenuates renal injury in experimental acute renal failure ischemic/reperfusion model. Nephrol Dial Transplant 2006;21:330–6.
6. Rjiba-Touati K, Boussema IA, Belarbia A, et al. Protective effect of recombinant human erythropoietin against cisplatin-induced oxidative stress and nephrotoxicity in rat kidney. Int J Toxicol 2011;30:510–17.
7. Maggioni D, Nicolini G, Chiorazzi A, et al. Different effects of erythropoietin in cisplatin- and docetaxel-induced neurotoxicity: an in vitro study. J Neurosci Res 2010;88:3171–9.
8. Mohamed HE, El-Swefy SE, Mohamed RH, Ghanim AM., Effect of erythropoietin therapy on the progression of cisplatin induced renal injury in rats. Exp Toxicol Pathol 2013;65:197–203.
9. Eshraghi-Jazi F, Nematbakhsh M, Pezeshki Z, et al. Sex differences in protective effect of recombinant human erythropoietin against cisplatin-induced nephrotoxicity in rats. Iran J Kidney Dis 2013;7:383–9.
10. Pezeshki Z, Nematbakhsh M, Mazaheri S, et al. Estrogen abolishes protective effect of erythropoietin against cisplatin-induced nephrotoxicity in ovariectomized rats. ISRN Oncol 2012;2012:890310.
11. Durlinger AL, Kramer P, Karels B, et al. Control of primordial follicle recruitment by anti-Müllerian hormone in the mouse ovary. Endocrinology 1999;140:5789–96.
12. Osman P., Rate and course of atresia during follicular development in the adult cyclic rat. J Reprod Fertil 1985;73:261–70.
13. Guven S, Muci E, Unsal MA, et al. The effects of carbon dioxide pneumoperitoneum on ovarian blood flow, oxidative stress markers, and morphology during laparoscopy: a rabbit model. Fertil Steril 2010;93:1327–32.
14. Hardee ME, Arcasoy MO, Blackwell KL, et al. Erythropoietin biology in cancer. Clin Cancer Res 2006;15:332–9.
15. Bakan V, Ciralik H, Tolun FI, et al. Protective effect of erythropoietin on torsion/detorsion injury in rat model. J Pediatr Surg 2009;44:1988–94.
16. Yasuda Y, Masuda S, Chikuma M, et al. Estrogen dependent production of erythropoietin in uterus and its implication in uterine angiogenesis. J Biol Chem 1998;273:25381–7.
17. Ergun Y, Koc A, Dolapcioglu K, et al. The protective effect of erythropoietin and dimethylsulfoxide on ischemia-reperfusion injury in rat ovary. Eur J Obstet Gynecol Reprod Biol 2010;152:186–90.
18. Karaca M, Odabasoglu F, Kumtepe Y, et al. Protective effects of erythropoietin on ischemia/reperfusion injury of rat ovary. Eur J Obstet Gynecol Reprod Biol 2009;144:157–62.
19. Solaroglu A, Kaptanoglu E, Dede S, et al. Erythropoietin prevents ischemia reperfusion from inducing oxidative damage in fetal rat brain. Childs Nerv Syst 2003;19:19–22.
20. Visser JA, de Jong FH, Laven JS, Themmen AP., Anti-Mullerian hormone: a new marker for ovarian function. Reproduction 2006;131:1–9.
21. van Rooij IA, Broekmans FJ, te Velde ER, et al. Serum anti-Müllerian hormone levels: a novel measure of ovarian reserve. Hum Reprod 2002;17:3065–71.
22. Yeh J, Kim B, Liang YJ, Peresie J., Mullerian inhibiting substance as a novel biomarker of cisplatin-induced ovarian damage. Biochem Biophys Res Commun 2006;348:337.
23. Erbaş O, Akman L, Yavaşoğlu A, et al. Oxytocin improves follicular reserve in a cisplatin-induced gonadotoxicity model in rats. Biomed Res Int 2014;2014:703691.
24. Yucebilgin MS, Terek MC, Ozsaran A, et al. Effect of chemotherapy on primordial follicular reserve of rat: an animal model of premature ovarian failure and infertility. Aust N Z J Obstet Gynaecol 2004;44:6–9.
25. Taskin MI, Yay A, Adali E, et al. Protective effects of sildenafil citrate administration on cisplatin-induced ovarian damage in rats. Gynecol Endocrinol 2015;31:272–7.
26. Li X, Yang S, Lv X, et al. The mechanism of mesna in protection from cisplatin-induced ovarian damage in female rats. J Gynecol Oncol 2013;24:177–85.
27. Tan SJ, Yeh YC, Shang WJ, et al. Protective effect of a gonadotropin-releasing hormone analogue on chemotherapeutic agent-induced ovarian gonadotoxicity: a mouse model. Eur J Obstet Gynecol Reprod Biol 2010;149:182–5.
28. Lemos CN, Reis FM, Pena GN, et al. Assessment of fertility protection and ovarian reserve with GnRH antagonist in rats undergoing chemotherapy with cyclophosphamide. Reprod Biol Endocrinol 2010;8:51.
29. Kaya C, Turgut H, Cengiz H, et al. The effect of tubal sterilization with the Pomeroy technique and bipolar electrocauterization on the ovarian reserve and serum anti-Müllerian hormone levels in a rat model. Eur J Obstet Gynecol Reprod Biol 2015;185:108–13.
30. Lebwohl D, Canetta R., Clinical development of platinum complexes in cancer therapy: an historical perspective and an update. Eur J Cancer 1998;34:1522–34.
31. Akdemir A, Sahin C, Erbas O, et al. Is ursodeoxycholic acid crucial for ischemia/reperfusion-induced ovarian injury in rat ovary? Arch Gynecol Obstet 2015;292:445–50.
32. Maiese K, Chong ZZ, Li F, Shang YC., Erythropoietin: elucidating new cellular targets that broaden therapeutic strategies. Prog Neurobiol 2008;85:194–213.